AFP Test: Tumor Marker Levels & Liver Cancer Detection
AFP, or alpha-fetoprotein, is a tumor marker primarily associated with hepatocellular carcinoma (liver cancer) and testicular cancer. AFP is also produced during normal fetal development but decreases after birth to very low adult levels. Elevated AFP warrants investigation in at-risk populations, particularly those with chronic liver disease. Understanding AFP results requires integrating measurements with imaging studies and clinical assessment of liver disease severity.
Understanding AFP Test Results Online
Interpreting your AFP test results online helps you understand this important liver and testicular cancer marker. AFP is measured in nanograms per milliliter (ng/mL), with values above 20 ng/mL typically considered elevated in adults. Results should be interpreted by a healthcare provider considering your individual risk factors, liver disease status, and imaging findings. Serial AFP measurements and trends over time often provide more clinical value than a single measurement for cancer surveillance.
What is Alpha-Fetoprotein and Why it Matters
Alpha-fetoprotein is a protein produced during normal fetal development that typically decreases to nearly undetectable levels after birth. Elevated AFP in adults usually indicates either hepatocellular carcinoma or testicular cancer, particularly non-seminomatous germ cell tumors. AFP is also produced by some other malignancies including gastric cancer and certain pancreatic tumors. In patients with chronic liver disease and cirrhosis, AFP serves as an important surveillance marker for hepatocellular carcinoma development.
Normal AFP Levels and Cancer Risk
Normal AFP levels in healthy adults are typically below 20 ng/mL (some labs use 10 ng/mL). In chronic liver disease, gradually rising AFP can indicate development of hepatocellular carcinoma even before imaging findings appear. Approximately 60-70% of advanced hepatocellular carcinomas have elevated AFP, while early-stage cancers may have normal or borderline levels. The combination of AFP measurement with ultrasound and CT imaging provides the most sensitive detection of hepatocellular carcinoma in at-risk patients.
Elevated AFP: Liver Disease and Cancer Causes
Elevated AFP can result from active viral hepatitis (hepatitis B and C), cirrhosis, benign liver adenomas, and other liver diseases besides cancer. Non-seminomatous testicular germ cell tumors consistently elevate AFP, particularly non-embryonal cell carcinomas. Some gastric cancers and pancreatic cancers also raise AFP. Even benign liver diseases can cause mild AFP elevation. Therefore, elevated AFP requires evaluation with imaging (ultrasound, CT, MRI) and specialist consultation to determine underlying cause.
AFP Monitoring: Screening and Cancer Management
AFP surveillance is recommended for patients with chronic hepatitis B or cirrhosis at high risk for hepatocellular carcinoma, typically with testing every 3-6 months combined with abdominal ultrasound. Rapid AFP doubling time or absolute levels above 400 ng/mL strongly suggest hepatocellular carcinoma development. In testicular cancer patients, markedly elevated AFP (often >1000 ng/mL) indicates non-seminomatous tumors requiring aggressive chemotherapy. Serial AFP measurement during and after cancer treatment helps assess treatment response and detect early recurrence for potential salvage therapy.
How to interpret your AFP results
An AFP result is a single number on a lab report, but its meaning depends almost entirely on context — who you are, why the test was ordered, and what other findings sit alongside it. The same value can be reassuring in one situation and a concern in another.
The first thing to clarify is which AFP test was run. The standard adult test reports total AFP as a tumor marker in your blood. A less common version, AFP-L3%, reports a subfraction used to assess liver cancer risk in people with chronic liver disease. A third type of AFP test exists in pregnancy care — it is a screening test for fetal birth defects rather than a tumor marker, and the two cannot be interpreted interchangeably.
Single value vs. trend
For tumor-marker AFP, a single number is rarely the whole story. If you are being followed for known cancer or for chronic hepatitis or cirrhosis, the trajectory matters more than any individual reading. During cancer treatment, AFP that is decreasing usually suggests treatment is working, stable AFP suggests stable disease, and rising AFP can indicate that the cancer is progressing or returning.
Borderline and unexpected results
If you have no known cancer and your AFP is moderately elevated, that does not by itself mean cancer is present. Liver injury and non-cancerous liver diseases can also raise AFP. Hepatic damage and the regeneration that follows, as well as some hereditary and non-hepatic conditions, can drive AFP up without any tumor involvement. Conversely, a normal AFP does not rule cancer out — some people with liver, ovarian, or testicular cancer have normal AFP levels. Both findings need to be discussed with the clinician who ordered the test, who can place the result against your full history, imaging, and other labs.
AFP across cancer types: liver, germ cell, and other tumors
AFP is most strongly associated with hepatocellular carcinoma (HCC), the most common form of liver cancer, but it is genuinely a multi-cancer marker. The National Cancer Institute lists AFP as a blood-based tumor marker used in liver cancer, ovarian cancer, and germ cell tumors. Its clinical roles include helping diagnose these cancers, following response to treatment, and assessing stage, prognosis, and treatment response in germ cell tumors.
Liver cancer
In HCC, AFP is typically used together with imaging rather than on its own. The marker has known limitations in sensitivity and specificity for HCC, which is why current practice combines AFP with ultrasound or other imaging in people at risk. In the broader clinical picture, AFP can also help monitor people with chronic hepatitis or cirrhosis, who carry a higher risk of developing liver cancer over time.
Germ cell tumors
AFP is informative in non-seminomatous testicular germ cell tumors and in certain ovarian germ cell tumors. In this setting it is used not only to help confirm a diagnosis but also to assess stage, prognosis, and how well treatment is working in germ cell tumors. After treatment, AFP can be repeated periodically to check for recurrence in cancers that originally caused it to rise.
Less common associations
Beyond these primary uses, less commonly, high AFP can be a sign of other cancers, including lymphoma and lung cancer. AFP is not a screening test for these — it is mentioned because an unexpectedly elevated AFP sometimes prompts a wider workup. Related blood tumor markers, including CEA and CA-125, are sometimes used alongside AFP when the differential diagnosis spans several organs.
AFP-L3 and advanced AFP testing
Total AFP is useful but blunt. Researchers and clinicians have looked for ways to make AFP-based testing more accurate, especially for picking up early HCC in people with chronic liver disease. AFP-L3 is one of the most clinically established refinements.
What AFP-L3% measures
AFP-L3 is a specific form of alpha-fetoprotein. The AFP-L3 percent test (AFP-L3%) compares the amount of L3 to the amount of total AFP in your blood. If the proportion of L3 rises, it can indicate a higher risk of developing hepatocellular carcinoma, the most common form of liver cancer. AFP-L3% is sometimes ordered in people with chronic liver disease whose total AFP is mildly elevated, where the question is whether that elevation is from underlying liver damage or from an emerging tumor.
Combination biomarker panels
AFP-L3 is part of a broader move toward combination biomarkers. The combination of AFP with novel biomarkers such as AFP-L3, Golgi-specific membrane protein (GP73), and des-gamma-carboxyprothrombin (DCP) significantly improves accuracy in detecting HCC compared with AFP alone. DCP is independently recognized as an HCC blood marker used to monitor treatment effectiveness and detect recurrence.
In practice, the panel a clinician orders depends on local lab availability, the underlying liver disease, and the clinical question — initial workup, surveillance, treatment monitoring, or recurrence detection. None of these markers replaces imaging, and the choice of which to order is a clinical decision rather than a self-directed one.
Limitations and false positives of AFP testing
AFP is a useful marker, but it has well-known shortcomings. Understanding them is part of reading any result responsibly.
Why AFP alone cannot rule cancer in or out
The MedlinePlus patient resource is explicit: an AFP tumor marker test cannot be used by itself to screen for or diagnose cancer. Two problems pull in opposite directions:
- False reassurance. Some people with liver, ovarian, or testicular cancer have normal AFP levels, so a normal result does not rule out cancer.
- False alarm. Other conditions raise AFP, including non-cancerous liver diseases. Acute and chronic liver conditions and cirrhosis can elevate AFP because of the hepatic destruction and subsequent regeneration involved, and hereditary or other non-hepatic disorders can also cause AFP to rise.
Laboratory and method limitations
Beyond biology, the test itself has measurement limits. The literature describes low sensitivity and specificity for HCC and discrepancies among the different methods of measurement, with accuracy varying by patient characteristics and the cut-off values a given lab uses. That is one practical reason clinicians prefer to compare AFP values from the same lab over time rather than mixing results from different labs.
ELISA-based AFP assays are also vulnerable to interfering antibodies in the patient’s blood. These antibodies can bind directly to the test reagents and emit signal without actual AFP being present, producing false positive results; alternatively, they can block reagent-antibody binding and produce false negative results.
Hereditary persistence of AFP
A small number of people have hereditary persistence of alpha-fetoprotein — a benign condition in which AFP stays elevated through adulthood without any liver damage or tumor. The pubmed literature on AFP for HCC names hereditary persistence of alpha-fetoprotein among the conditions that can confound interpretation. It is uncommon, but worth knowing about when an unexplained mild elevation is found repeatedly in someone with no liver disease.
AFP in pregnancy: maternal serum screening
A separate test called maternal serum AFP (MSAFP) is used in pregnancy. It measures the same protein but is run and interpreted very differently from the tumor-marker test. MedlinePlus is clear that this prenatal AFP test is not a tumor marker test for cancer — it is used to check for the risk of certain birth defects in an unborn baby.
Outside of pregnancy, AFP is normally very low in adults because it is mainly a fetal protein; after birth, AFP levels drop very low. During pregnancy, maternal blood levels of AFP can suggest a higher chance of certain fetal conditions. An abnormal MSAFP screen is not a diagnosis on its own. Follow-up testing such as detailed ultrasound or further evaluation by an obstetric clinician is needed to clarify what the screen actually means.
If you are pregnant and AFP screening has been suggested or your result is abnormal, the right next step is a conversation with your obstetric provider rather than reading tumor-marker reference ranges. The numbers, units, and cut-offs used for prenatal AFP screening are not the same as those used for tumor-marker AFP, and the two should not be compared.
When to talk to your doctor
AFP results are designed to be interpreted by a clinician who knows your full picture, not by a calculator on a results portal. Reach out to your healthcare provider in the following situations:
- Your AFP is elevated and you have no known cancer. Even a moderate elevation should be discussed, because non-cancerous liver injury and other conditions can also raise AFP, and your provider will decide whether imaging or repeat testing is warranted.
- You have chronic hepatitis or cirrhosis and your AFP is suddenly higher or very high. A sudden increase or markedly elevated AFP can be an early sign of liver cancer, and other tests may be needed to investigate.
- You are being treated for a cancer that raised your AFP and your level is rising or has plateaued during treatment. Rising AFP during therapy may mean the treatment is not working; stable or falling values may indicate the opposite.
- You have completed cancer treatment and a follow-up AFP is higher than it was shortly after treatment ended. That pattern can suggest the cancer is growing again and warrants prompt re-evaluation.
- You are pregnant and have been told your maternal serum AFP screen is abnormal. Your obstetric provider can arrange follow-up such as ultrasound or further evaluation; the prenatal test is a screen, not a diagnosis.
- You have repeated mild AFP elevations with no obvious cause. Conditions such as hereditary persistence of AFP and various non-hepatic disorders can produce persistent low-grade elevations, and your provider can help decide whether further workup is needed.
If you are also tracking liver-related labs alongside AFP — for example ALT or bilirubin — bring those results to the same visit. A clinician reading AFP in isolation is working with less information than one who can see the whole liver-health picture.
Frequently asked questions
What is an AFP blood test?
An AFP blood test measures alpha-fetoprotein, a protein the liver makes when its cells are growing and dividing. In adults who are not pregnant, it is mainly used as a tumor marker to help diagnose and monitor cancers of the liver, ovaries, or testicles.
What does the AFP test check for?
In adults, the AFP tumor marker test helps doctors evaluate possible cancers of the liver, ovaries, or testicles, monitor how well cancer treatment is working, and check whether a cancer has returned after treatment. The National Cancer Institute lists AFP specifically for liver cancer, ovarian cancer, and germ cell tumors.
Is the AFP test used for liver cancer alone?
No. AFP is most strongly linked to hepatocellular carcinoma but is also used in ovarian cancer and germ cell tumors, and less commonly may be elevated in other cancers such as lymphoma or lung cancer. It is not specific to a single organ.
When is an AFP test done?
It is typically ordered when a physical exam or other tests suggest possible liver, ovarian, or testicular cancer; during treatment for one of these cancers to monitor response; or after treatment to watch for recurrence. People with chronic hepatitis or cirrhosis may also be tested as part of liver-cancer surveillance.
Do I need to prepare for an AFP test?
No special preparation is required. A healthcare professional takes a blood sample from a vein in your arm, which usually takes less than five minutes, and risks are limited to mild discomfort or bruising at the needle site.
What is the AFP-L3 test?
AFP-L3 is a specific form of AFP. The AFP-L3% test compares the amount of L3 to the total AFP in your blood; a rising L3 proportion can indicate higher risk of developing hepatocellular carcinoma in people with chronic liver disease.
Is the AFP test in pregnancy the same as the cancer test?
No. The pregnancy version measures total AFP in maternal blood as a screening test for certain birth defects in the unborn baby, not as a cancer marker. The reference ranges, interpretation, and clinical follow-up differ from the tumor-marker test.
How much does an AFP test cost?
Costs vary substantially by lab, region, insurance plan, and whether the test is run alone or as part of a panel. The reference sources used here do not list specific prices, so the best path is to ask the ordering clinician’s office or your insurer for an estimate before the draw.
References
- MedlinePlus (U.S. National Library of Medicine, NIH)
- Peer-reviewed reference
- PubMed (U.S. National Library of Medicine, NIH)